Expertise in
2
conditions

Dr. Antoinette J. Wozniak

Hematology
Office
5150 Centre Ave, 
Pittsburgh, PA 
Expertise in
2
conditions
Office
5150 Centre Ave, 
Pittsburgh, PA 

Overview

Antoinette Wozniak is a Hematologist practicing medicine in Pittsburgh, Pennsylvania.

Dr. Wozniak is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Febrile Neutropenia, Agranulocytosis, and Hairy Cell Leukemia (HCL).

She is actively involved in clinical research, co-authoring 56 peer reviewed articles and participating in 25 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO

Locations

Office
5150 Centre Ave, Pittsburgh, PA 15232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: Bevacizumab, Cisplatin, Docetaxel, Etoposide, Filgrastim, Pegfilgrastim
Study Phase: Phase 2
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)
Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Device
Study Drug: 3'-Deoxy-3'-18F Fluorothymidine
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Radiation, Procedure, Drug
Study Drugs: Atezolizumab, Cisplatin, Pemetrexed Disodium
Study Phase: Phase 1
A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.
A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Other
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
View 9 Less Clinical Trials

56 Total Publications

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.
Global advances and future directions in lung cancer care: expert consensus and strategic priorities.
Journal: ESMO open
Published: November 15, 2025
Similar Doctors
Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required
Before you request

Classical Hematology

3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 
 (1.0 miles away)
412-586-9875
Languages Spoken:
English, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Enrico M. Novelli, MD, is a classical (benign) hematologist, the Chief of the Section of Benign Hematology, and the medical director of the UPMC Adult Sickle Cell Disease Program. Board-certified in hematology, Dr. Novelli received his medical degree from the University of Milan, Italy. He completed his residency in internal medicine and fellowship in hematology-oncology at UPMC. Dr. Novelli specializes in sickle cell anemia and hemoglobinopathies. Dr. Novelli is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy. Dr. Novelli is board certified in American Board Of Internal Medicine. Dr. Novelli is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
Before you request

Classical Hematology

3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 
 (1.0 miles away)
412-586-9875
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Seaman is a Hematologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Seaman is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Von Willebrand Disease (VWD), Hemophilia A, Blood Clots, and Hemophilic Arthropathy. Dr. Seaman is board certified in American Board Of Internal Medicine. Dr. Seaman is currently accepting new patients.

Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

Univ. Of Pittsburgh Cancer Institute Cancer Services

5115 Centre Ave Fl 3, 
Pittsburgh, PA 
 (0.5 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mounzer Agha is a Hematologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Agha is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Agha is currently accepting new patients.

Frequently Asked Questions about Dr. Antoinette J. Wozniak

How do I make an appointment with Dr. Antoinette J. Wozniak?

You can book an appointment with Dr. Antoinette J. Wozniak by calling their office at 412-692-4724. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Antoinette J. Wozniak a top-rated expert for ALK-Positive Non-Small Cell Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Antoinette J. Wozniak is classified as an Distinguished expert for ALK-Positive Non-Small Cell Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Antoinette J. Wozniak specialize in?

While Dr. Antoinette J. Wozniak is a Hematology, they have specific expertise in ALK-Positive Non-Small Cell Lung Cancer, Febrile Neutropenia, and Agranulocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Antoinette J. Wozniak participate in research or clinical trials?

Yes. Dr. Antoinette J. Wozniak has published 56 articles and abstracts on conditions like ALK-Positive Non-Small Cell Lung Cancer. You can view a list of Dr. Antoinette J. Wozniak's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Antoinette J. Wozniak accept my insurance?

Dr. Antoinette J. Wozniak accepts most major insurance plans, including Cigna and Humana. We recommend calling the office directly at 412-692-4724 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wozniak's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile